Published in Blood Weekly, April 12th, 2001
John E. Janik and colleagues at the U.S. National Institutes of Health investigated the effectiveness both of GM-CSF treatment in blocking myelosuppression and of topotecan chemotherapy in destroying melanoma and renal tumors. They found that both the severity and duration of white blood cell deficiency after topotecan chemotherapy were significantly reduced by priming with GM-CSF.
Under normal circumstances, roughly 20% of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.